A detailed history of Lgt Group Foundation transactions in Abb Vie Inc. stock. As of the latest transaction made, Lgt Group Foundation holds 80,454 shares of ABBV stock, worth $15.9 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
80,454
Previous 10,322 679.44%
Holding current value
$15.9 Million
Previous $1.88 Million 634.38%
% of portfolio
0.21%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$154.79 - $180.76 $10.9 Million - $12.7 Million
70,132 Added 679.44%
80,454 $13.8 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $310,530 - $353,820
-1,943 Reduced 15.84%
10,322 $1.88 Million
Q4 2023

Feb 06, 2024

SELL
$137.6 - $154.97 $369,868 - $416,559
-2,688 Reduced 17.98%
12,265 $1.9 Million
Q3 2023

Nov 06, 2023

BUY
$133.59 - $154.65 $228,305 - $264,296
1,709 Added 12.9%
14,953 $2.23 Million
Q2 2023

Jul 27, 2023

BUY
$132.51 - $164.9 $105,345 - $131,095
795 Added 6.39%
13,244 $1.78 Million
Q1 2023

Apr 20, 2023

SELL
$144.61 - $166.54 $344,750 - $397,031
-2,384 Reduced 16.07%
12,449 $1.98 Million
Q4 2022

Feb 09, 2023

SELL
$138.31 - $165.87 $1.76 Million - $2.11 Million
-12,727 Reduced 46.18%
14,833 $2.4 Million
Q3 2022

Oct 19, 2022

SELL
$134.21 - $153.93 $307,206 - $352,345
-2,289 Reduced 7.67%
27,560 $3.7 Million
Q2 2022

Aug 03, 2022

SELL
$137.62 - $174.96 $259,964 - $330,499
-1,889 Reduced 5.95%
29,849 $4.57 Million
Q1 2022

May 11, 2022

SELL
$131.98 - $163.75 $4.63 Million - $5.74 Million
-35,056 Reduced 52.48%
31,738 $5.16 Million
Q4 2021

May 03, 2022

BUY
$107.43 - $135.93 $7.18 Million - $9.08 Million
66,794 New
66,794 $9.04 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $349B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lgt Group Foundation Portfolio

Follow Lgt Group Foundation and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lgt Group Foundation, based on Form 13F filings with the SEC.

News

Stay updated on Lgt Group Foundation with notifications on news.